Long-Term Follow-Up Data Show Consistent, Durable Response t

Results from the VALOR-HCM LTE trial at 56 weeks demonstrated that with longer follow-up, mavacamten continued to reduce patient eligibility for invasive septal reduction therapy.

Related Keywords

Madrid , Spain , United States , Amy Sehnert , Pablo Garcia Pavia , Milind Desai , York Heart Association , Thoracic Institute At Cleveland Clinic , Bristol Myers Squibb , European Union , New York Heart Association , Hypertrophic Cardiomyopathy , Thoracic Institute , Cleveland Clinic , Inherited Cardiac Diseases , Heart Failure Unit , Hospital Universitario Puerta De Hierro ,